Exploring New Avenues for Multiple Sclerosis Treatment
Grace Miller, now 46 and living in Fishers, Indiana, was diagnosed with multiple sclerosis (MS) when she was just 24 years old while studying law. Before her diagnosis, she experienced extreme fatigue, which a neurologist initially attributed to narcolepsy. However, after she suffered from episodes of vertigo and temporary vision loss, the diagnosis shifted.
For 15 years, Miller endured the side effects of two different medications that left her feeling unwell every time she received a new dose. Her vision fluctuated, and in 2021, she began using a cane to assist her walking. “I used to work as a lawyer, but reading a book is not even an option anymore,” she shared, reflecting on her struggles.
Last year, she took part in an early-stage clinical trial at the Cleveland Clinic, exploring a cancer therapy that researchers hope could be a breakthrough for MS. This therapy, called CAR-T, has already made waves in treating cancer patients.
During CAR-T therapy, doctors extract a patient’s T cells—immune cells that combat infections—reprogramming them to attack proteins present in tumor cells. When reintroduced to the body, these T cells transform into agents that fight cancer, notably effective against cancers affecting B cells, such as leukemia and lymphoma.
Interestingly, overactive B cells are also significant players in multiple sclerosis. They can attack myelin, the protective covering on nerve fibers. Without this myelin, nerve signals become sluggish or blocked. While various treatments exist to slow MS progression, there’s currently no cure. The disease can lead to loss of limb function, vision, and even memory issues over time.
CAR-T therapy might address the same overactive B cells targeted by existing MS medications, but with a distinct advantage. Current drugs struggle to penetrate the brain and central nervous system where some B cells can hide, while CAR-T cells appear to be more capable of doing so. “They would not only eliminate B cells in the blood, similar to existing antibody therapies, but also those tucked away in the brain, which likely contribute to disease progression,” explained Dr. Jeffrey Cohen from the Cleveland Clinic.
Cohen underscored that current CAR-T trials for MS are in very early stages, so while there is optimism, it’s tempered with caution. He acknowledged the extensive prior experience in cancer treatments as a positive aspect but noted that the effectiveness of CAR-T for MS remains uncertain.
Across the nation, similar trials are being conducted in institutions like Stanford University and Columbia University. The Cleveland Clinic trial, supported by Bristol Myers Squibb, has included several individuals with MS, including two who have progressive MS and two with the relapsing form of the disease. The latter experiences bouts of attacks followed by recovery.
Typically, CAR-T involves just one infusion of the modified T cells. After T cells are extracted, patients undergo chemotherapy to make way for the reintroduced cells. Miller received her infusion last May, and although she still uses a cane, she has started to take more steps independently. “My friend brought her 18-month-old to my house, and I picked her up for the first time standing. I’ve never done that before,” Miller recalled, a mix of joy and disbelief evident in her voice.
Future Prospects
Yet, caution prevails. Researchers are still weighing the potential of CAR-T for MS, with some experts doubtful it could surpass the efficacy of existing treatments, especially for those with progressive MS where severe damage may already be present. Dr. Rhonda Voskuhl from UCLA expressed skepticism about the therapy’s effectiveness for progressive cases, suggesting that simply targeting inflammation might not be sufficient.
Unlike existing therapies, which do a proficient job, CAR-T may not address the need for restitution of neurological damage. “Repairing what’s broken is essential,” noted Dr. Enrique Alvarez from the Rocky Mountain MS Center, emphasizing the potential of stem cells for such regeneration.
Meanwhile, improving existing MS treatments remains vital. Some drugs, like ofatumumab, were originally designed for B cell leukemia and have shown promise. “Even if CAR-T doesn’t fulfill its potential, the insights gained from these trials about the immune system and MS will hold value,” Alvarez added.
As for the risks, CAR-T therapy can provoke severe reactions, including cytokine release syndrome, which can lead to serious inflammatory responses, as well as neurotoxicity issues particularly concerning in MS patients. Cohen acknowledged that unforeseen complications might arise since cancer patients and MS patients can respond differently to treatments. Thus, a balanced approach is essential as the research continues.
Overall, while the journey into CAR-T for MS holds promise, the path forward will require careful exploration and rigorous trials to assess its true potential.
